Darbepoetin alfa biosimilar - JCR Pharmaceuticals/Kissei Pharmaceutical

Drug Profile

Darbepoetin alfa biosimilar - JCR Pharmaceuticals/Kissei Pharmaceutical

Alternative Names: JR-131

Latest Information Update: 26 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator JCR Pharmaceuticals; Kissei Pharmaceutical
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Anaemia

Most Recent Events

  • 21 Sep 2016 JCR Pharmaceuticals and Kissei Pharmaceutical initiate a long-term phase III trial for Anaemia (associated with renal impairment) in Japan (Parenteral) before September 2016 (NCT02912533)
  • 09 Aug 2016 Phase-III clinical trials in Anaemia in Japan (Parenteral) (JCR Pharmaceuticals pipeline, August 2016; 9202314; NCT02912494)
  • 29 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top